The purpose of this study is to examine the insulin-sparing effect of sitagliptin 100 mg
once-daily compared with placebo over 24 weeks in participants with type 2 diabetes mellitus
who have inadequate glycemic control on insulin alone or in combination with metformin. The
primary hypothesis of this study is that after 24 weeks, sitagliptin reduces the dose of
insulin relative to placebo.